CureMatch is the only company to offer a data-driven report that scores combinations of cancer drugs that are tailored for individual patients. The report is generated using CureMatch's Decision Support System, which can analyze millions of cancer treatment options with its proprietary algorithms and evidence-based, custom-curated databases of genomics and proteomics information.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/16/17 | undisclosed | Bridge |
Phil Trubey Serra Ventures | undisclosed |
